# Seminar 10: Gynecologic History and Examination

## OB/GYN Clerkship

---

## Learning Objectives

By the end of this seminar, students will be able to:

1. Obtain a comprehensive gynecologic history including menstrual, obstetric, sexual, and contraceptive components
2. Perform a systematic pelvic examination with proper patient preparation and chaperone protocols
3. Execute speculum and bimanual examination techniques and interpret cervical findings
4. Apply current ASCCP/ACOG cervical cancer screening guidelines and manage abnormal Pap smear results
5. Conduct a clinical breast examination and evaluate common breast findings using appropriate imaging modalities
6. Deliver well-woman preventive care across special populations including adolescents, menopausal women, and LGBTQ+ patients

---

## Seminar Outline

### Section 1: Gynecologic History

The gynecologic history begins with a thorough chief complaint and history of present illness focused on the reproductive system. Key areas of inquiry include menstrual symptoms such as the last menstrual period, cycle length, duration, and flow characteristics. Bleeding patterns should be explored including any abnormal pattern, postcoital bleeding, or postmenopausal bleeding. Pain symptoms warrant detailed characterization encompassing pelvic pain, dysmenorrhea, and dyspareunia, while vaginal discharge should be described by color, odor, and consistency. Urinary complaints including frequency, urgency, and incontinence complete the review of the chief complaint.

The menstrual history establishes critical baseline parameters for reproductive health assessment. Normal menarche occurs between ages 10 and 16 years, with a typical cycle length of 24 to 38 days and menstrual duration of 4 to 8 days. Normal menstrual blood loss ranges from 20 to 80 milliliters per cycle, and cycle regularity is considered normal with variation of plus or minus 7 to 9 days. Deviations from these parameters may indicate underlying pathology and should prompt further evaluation depending on the clinical context.

The obstetric history captures a woman's complete pregnancy experience and is documented using a standardized format. Gravidity records the total number of pregnancies, while parity is expressed using the TPAL system representing term deliveries, preterm deliveries, abortions or miscarriages, and living children. Each pregnancy outcome should be detailed including the mode of delivery, whether vaginal or cesarean, and any associated complications. Pregnancy losses require documentation of the gestational age at loss and the management approach, whether expectant, medical, or surgical.

The sexual and contraceptive history addresses intimate aspects of patient health with sensitivity and without assumptions. Clinicians should inquire about current sexual activity and the number and gender of partners, using inclusive language. Contraceptive history includes current and past methods along with satisfaction and any side effects experienced. A complete sexually transmitted infection history documents prior infections, treatments, and any residual concerns. Questions regarding sexual satisfaction and any dysfunction should be raised to identify issues that may affect quality of life and reproductive health.

<image>Panel A: Standardized gynecologic history intake form showing chief complaint categories including menstrual, bleeding, pain, discharge, and urinary domains. Panel B: Graphical representation of normal menstrual cycle parameters with cycle length of 24 to 38 days, duration of 4 to 8 days, and flow of 20 to 80 milliliters. Panel C: TPAL documentation system diagram illustrating gravidity and parity recording for obstetric history. Panel D: Sexual history framework demonstrating inclusive language approaches for partner assessment, contraceptive review, and STI screening.</image>

### Section 2: Pelvic Examination

The pelvic examination is a fundamental component of gynecologic evaluation, performed for a range of clinical indications. These include cervical cancer screening via Pap smear, evaluation of symptoms such as vaginal discharge, pelvic pain, or abnormal bleeding, and screening for sexually transmitted infections with or without speculum examination. The examination is also indicated for the diagnostic evaluation of pelvic pain, pregnancy confirmation, and assessment of pelvic masses or other structural abnormalities. The decision to perform a pelvic examination should be guided by clinical need rather than routine scheduling, particularly in asymptomatic younger patients.

Proper equipment preparation ensures a complete and efficient examination. The speculum, available in various sizes, allows visualization of the cervix and vaginal walls. A cytology brush and spatula are necessary for Pap smear collection, while swabs facilitate culture collection and wet preparation. Water-soluble lubricant is used for the bimanual examination, and standard precautions require the use of gloves throughout. An adequate light source is essential for visualization, and all equipment should be arranged within easy reach before the examination begins.

Patient preparation is critical to both the diagnostic quality and the patient's emotional experience of the examination. The clinician should provide a clear explanation of each step before proceeding, and verbal or written consent should be obtained. A chaperone is recommended for all pelvic examinations regardless of the clinician's gender, serving both to support the patient and to protect the clinician. The patient is positioned in dorsal lithotomy with feet in stirrups, and measures to enhance comfort include warming the speculum, encouraging relaxation through slow breathing, and maintaining communication throughout.

The external examination follows a systematic approach beginning with inspection of the mons pubis for hair distribution patterns that may indicate endocrine abnormalities. The labia majora and minora are examined for lesions, swelling, or asymmetry, and the clitoris is assessed for size and lesions. The urethral meatus is inspected for discharge or caruncle formation, while the vaginal introitus is evaluated for prolapse, discharge, or masses. The perineum is examined for scars from prior episiotomy or laceration repair and for any lesions, and the perianal area is assessed for hemorrhoids, fissures, or other pathology.

<image>Panel A: Complete pelvic examination equipment tray showing speculum in multiple sizes, cytology brush, spatula, culture swabs, lubricant, gloves, and light source. Panel B: Step-by-step patient preparation protocol illustrating consent process, chaperone positioning, and lithotomy positioning with comfort measures. Panel C: External genital anatomy diagram with labeled structures including mons pubis, labia majora, labia minora, clitoris, urethral meatus, vaginal introitus, and perineum. Panel D: Clinical photographs of normal external examination findings contrasted with common abnormalities including Bartholin cyst and labial adhesions.</image>

### Section 3: Speculum and Bimanual Examination

The speculum examination is performed in a sequential manner to optimize visualization and specimen collection. The closed speculum is inserted at a 45-degree angle directed posteriorly to avoid the urethra, then rotated to horizontal and advanced toward the cervix. Once positioned, the blades are opened to expose the cervix, which should be clearly visible within the speculum aperture. Specimens for Pap smear or cultures are collected with the cervix in view, and upon withdrawal, the speculum is slowly closed while the vaginal walls are inspected for lesions, discharge, or structural changes.

Cervical findings during speculum examination vary widely between normal variants and pathologic conditions. A normal cervix appears pink and smooth with a visible external os that may be round in nulliparous women or slit-like in parous women. Ectropion, the visible extension of columnar epithelium onto the ectocervix, is a common benign finding particularly in young women and those on hormonal contraception. Nabothian cysts are benign mucus-retention cysts that appear as smooth, yellow-white elevations on the cervical surface. Cervicitis manifests as erythema, purulent discharge, and friability, while cervical polyps appear as pedunculated growths extending from the os that may cause irregular bleeding.

The bimanual examination assesses the internal pelvic organs through combined vaginal and abdominal palpation. The cervix is evaluated for position, mobility, and tenderness, with cervical motion tenderness suggesting peritoneal irritation as may occur in pelvic inflammatory disease or ectopic pregnancy. The uterus is assessed for size, shape, position (anteverted or retroverted), contour, and tenderness. The adnexa are palpated bilaterally for the presence of masses or tenderness, with recognition that normal ovaries may or may not be palpable depending on body habitus. The cul-de-sac is assessed for nodularity or masses, which may suggest endometriosis or malignancy.

The rectovaginal examination is not performed routinely but is indicated in specific clinical scenarios. It is particularly valuable for evaluating posterior masses and the cul-de-sac, which may be difficult to assess on bimanual examination alone. The rectovaginal septum is examined for nodularity, which is a hallmark finding in deep infiltrating endometriosis. Additionally, rectal pathology such as hemorrhoids, fissures, or masses can be identified. The clinician should explain the purpose and technique before performing this examination and should note that a change of gloves is required between the bimanual and rectovaginal components.

<image>Panel A: Sequential illustration of speculum insertion technique showing 45-degree angle entry, horizontal rotation, blade opening, and cervical visualization. Panel B: Comparison images of cervical findings including normal cervix, ectropion, nabothian cysts, cervicitis with friability, and cervical polyp. Panel C: Bimanual examination technique demonstrating simultaneous vaginal and abdominal hand placement for uterine and adnexal assessment. Panel D: Rectovaginal examination positioning and technique with anatomical cross-section showing assessment of the rectovaginal septum and cul-de-sac.</image>

### Section 4: Cervical Cancer Screening

Current cervical cancer screening guidelines, updated by ASCCP and ACOG in 2020, are stratified by patient age. No screening is recommended before age 21 regardless of sexual activity onset. Between ages 21 and 29, cytology alone is performed every 3 years. For women aged 30 to 65, the preferred approach is HPV and cytology co-testing every 5 years, though primary HPV testing alone every 5 years or cytology alone every 3 years are acceptable alternatives. Screening may be discontinued after age 65 if the patient has had adequate prior negative screening results and is not at high risk.

Pap smear collection requires proper technique to ensure an adequate sample from the transformation zone. The cytology brush is inserted into the cervical os and rotated 360 degrees to collect endocervical cells, while the spatula is rotated around the transformation zone to collect ectocervical cells. The collected specimen is transferred to a liquid-based medium or applied directly to a glass slide, depending on the laboratory system. Proper patient identification and labeling of specimens is essential, and clinicians should avoid collecting samples during active menstruation or after recent intercourse, douching, or intravaginal medication use.

Cytology results are reported using the Bethesda classification system, which standardizes terminology for cervical specimens. A result of NILM indicates negative for intraepithelial lesion or malignancy and represents a normal finding. ASC-US denotes atypical squamous cells of undetermined significance, the most common abnormality, while LSIL represents low-grade squamous intraepithelial lesion often associated with transient HPV infection. HSIL indicates high-grade squamous intraepithelial lesion with greater concern for precancerous changes, and ASC-H describes atypical squamous cells in which HSIL cannot be excluded. AGC, atypical glandular cells, requires prompt evaluation due to its association with significant pathology including adenocarcinoma.

Management of abnormal cytology results follows evidence-based algorithms that consider the specific result, HPV status, and patient age. ASC-US is managed with reflex HPV testing or repeat cytology in one year, with colposcopy indicated if HPV is positive. LSIL in women aged 25 and older typically warrants colposcopy, while in younger women surveillance may be appropriate given the high likelihood of spontaneous regression. HSIL requires colposcopy regardless of age, and expedited treatment may be offered for patients aged 25 and older with HSIL cytology and positive high-risk HPV. AGC mandates both colposcopy and endometrial sampling, as glandular abnormalities may originate from the endocervix or endometrium.

<image>Panel A: Age-stratified cervical cancer screening algorithm showing no screening before 21, cytology alone from 21 to 29, and co-testing or primary HPV testing from 30 to 65. Panel B: Pap smear collection technique demonstrating endocervical brush rotation in the os and spatula sweep across the transformation zone with transfer to liquid medium. Panel C: Bethesda classification hierarchy showing progression from NILM through ASC-US, LSIL, HSIL, ASC-H, and AGC with corresponding risk levels. Panel D: Management flowchart for abnormal cytology results including reflex HPV testing for ASC-US, colposcopy for LSIL and HSIL, and combined colposcopy with endometrial sampling for AGC.</image>

### Section 5: HPV and Colposcopy

Human papillomavirus testing plays a central role in modern cervical cancer screening and triage. High-risk HPV types including 16, 18, 31, 33, and 45 among others are associated with cervical cancer development, with HPV types 16 and 18 conferring the highest cancer risk and accounting for approximately 70 percent of cervical cancers. Low-risk HPV types, primarily 6 and 11, cause genital warts but do not progress to cancer. Primary HPV testing has been approved as a standalone screening modality for women aged 25 and older, reflecting its superior sensitivity for detecting high-grade cervical lesions compared to cytology alone.

Colposcopy is indicated for the evaluation of abnormal cervical cytology, positive HPV results requiring further assessment, and visible cervical lesions. Specific cytology results that warrant colposcopy include LSIL, HSIL, ASC-H, and AGC, while HPV-positive ASC-US also requires colposcopic evaluation. Any suspicious visible lesion on the cervix should be evaluated with colposcopy regardless of screening results. Persistent ASC-US or recurrent abnormalities after initial surveillance similarly warrant colposcopic assessment to exclude significant cervical pathology.

The colposcopy procedure involves magnified visualization of the cervix using a colposcope, typically at 6 to 40 times magnification. After speculum insertion, dilute acetic acid (3 to 5 percent) is applied to the cervix, causing abnormal epithelium to turn white, a finding termed acetowhite changes. Lugol iodine solution may also be applied, with abnormal cells failing to take up the stain due to their lack of glycogen. Targeted biopsies are taken from the most abnormal-appearing areas, and endocervical curettage is performed when the transformation zone extends into the canal or when no lesion is identified to explain the cytologic abnormality.

Cervical biopsy results guide subsequent management based on the degree of cervical intraepithelial neoplasia identified. CIN 1, representing mild dysplasia, is typically managed with surveillance as the majority of cases regress spontaneously, though treatment may be considered for persistent lesions. CIN 2 and CIN 3 represent moderate and severe dysplasia respectively and are generally treated with excisional procedures such as loop electrosurgical excision procedure or cold knife conization to remove the abnormal tissue. When invasive carcinoma is identified on biopsy, the patient requires formal staging and treatment planning, which may include radical surgery, radiation, chemotherapy, or a combination depending on the stage and histologic features.

<image>Panel A: HPV type classification showing high-risk types 16, 18, 31, 33, and 45 with associated cancer risk percentages, and low-risk types 6 and 11 associated with genital warts. Panel B: Colposcopy indications algorithm connecting abnormal cytology results and positive HPV testing to the decision for colposcopic evaluation. Panel C: Colposcopy procedure images showing normal cervix, acetowhite epithelium after acetic acid application, Lugol iodine non-staining areas, and targeted biopsy technique. Panel D: CIN management pathway from CIN 1 surveillance through CIN 2 and CIN 3 excisional treatment to invasive carcinoma staging and definitive therapy.</image>

### Section 6: Breast Examination

The clinical breast examination is performed systematically to identify abnormalities requiring further evaluation. Inspection is conducted with the patient in multiple positions including arms at sides, arms raised overhead, and hands on hips to contract the pectoralis muscles, each position potentially revealing different findings such as skin dimpling, nipple retraction, or asymmetry. Palpation is performed using either a circular or radial spoke pattern, ensuring that all breast tissue including the axillary tail is examined. The axillae are palpated for lymphadenopathy, which may indicate metastatic disease, and the nipples are gently compressed to check for discharge.

Concerning findings on breast examination require urgent evaluation and include a mass that is fixed, irregular in shape, or hard in consistency. Skin changes such as peau d'orange (resembling orange peel due to lymphatic obstruction) and dimpling suggest underlying malignancy with tethering to skin or Cooper ligaments. Nipple discharge that is bloody, unilateral, and spontaneous warrants investigation, as does new nipple retraction or inversion. Palpable axillary lymphadenopathy in the setting of a breast abnormality raises concern for regional metastatic disease and should prompt expedited imaging and tissue sampling.

Benign breast conditions account for the majority of breast findings in clinical practice. Fibroadenomas present as mobile, rubbery, well-circumscribed masses most commonly in young women and are the most common benign breast tumor. Breast cysts are smooth, round, and often tender in relation to the menstrual cycle, easily confirmed on ultrasound. Fibrocystic changes manifest as bilateral, diffuse tenderness and nodularity that fluctuates cyclically and represent the most common cause of breast complaints. Fat necrosis produces a palpable firm mass following breast trauma or surgery and may mimic carcinoma on physical examination, requiring imaging or biopsy for definitive diagnosis.

Evaluation of a breast mass follows an algorithm guided by patient age and imaging characteristics. Mammography is the initial imaging study for women aged 30 and older, while ultrasound is preferred as the first-line study in women under 30 due to the density of breast tissue in younger women. Ultrasound is also used to distinguish cystic from solid masses regardless of age. Breast MRI is reserved for high-risk screening or further characterization of indeterminate findings. Tissue diagnosis is obtained through core needle biopsy, which is preferred for its diagnostic accuracy and ability to provide histologic assessment, or excisional biopsy when core biopsy is inconclusive or discordant with imaging.

<image>Panel A: Clinical breast examination technique showing inspection in three positions (arms at sides, raised, hands on hips) and systematic palpation using radial spoke pattern with axillary assessment. Panel B: Concerning breast findings illustrated including fixed irregular mass, peau d'orange skin changes, bloody unilateral nipple discharge, and new nipple retraction. Panel C: Benign breast conditions showing fibroadenoma (mobile, rubbery), simple cyst (smooth, round), fibrocystic changes (bilateral nodularity), and fat necrosis (firm post-traumatic mass). Panel D: Breast mass evaluation algorithm showing age-based imaging approach with mammography for age 30 and older, ultrasound for under 30, and progression to core needle biopsy or excisional biopsy.</image>

### Section 7: Breast Cancer Screening

Mammography screening guidelines vary by organization, reflecting the complexity of balancing early detection benefits against screening harms. The American College of Obstetricians and Gynecologists recommends initiating screening mammography at age 40 with annual examinations. The US Preventive Services Task Force recommends biennial screening from ages 50 to 74, while the American Cancer Society suggests optional screening from 40 to 44, annual screening from 45 to 54, and biennial screening from age 55 onward. All organizations emphasize shared decision-making, in which the clinician discusses the benefits and risks of screening with each patient to arrive at an individualized plan.

High-risk patients require enhanced screening protocols beginning at an earlier age. Women with BRCA1 or BRCA2 mutations should undergo annual breast MRI in addition to mammography starting between ages 25 and 30. Those with a history of chest radiation, such as for Hodgkin lymphoma, should begin dual-modality screening eight years after radiation or at age 25, whichever comes later. Women with a strong family history undergo formal risk assessment using validated tools such as the Tyrer-Cuzick model, and screening recommendations are based on the calculated lifetime risk. Any woman with a personal history of breast cancer follows an individualized surveillance protocol.

The Breast Imaging Reporting and Data System (BI-RADS) provides a standardized classification for mammographic findings that guides clinical management. Category 0 indicates an incomplete assessment requiring additional imaging, while Category 1 is a negative result and Category 2 identifies definitively benign findings, both requiring only routine screening. Category 3 represents a probably benign finding with a recommendation for short-interval follow-up imaging at six months. Categories 4 and 5 indicate suspicious and highly suggestive findings respectively, both requiring tissue biopsy for definitive diagnosis. Category 6 is assigned to known biopsy-proven malignancies awaiting definitive treatment.

Breast density is an increasingly recognized factor in both cancer detection and risk assessment. Breast density is classified into four categories ranging from Category A (almost entirely fatty) through Category B (scattered fibroglandular densities) and Category C (heterogeneously dense) to Category D (extremely dense). Dense breast tissue, defined as Category C or D, is found in approximately 40 percent of women undergoing mammography and reduces the sensitivity of mammographic screening by obscuring masses. Furthermore, dense breast tissue is independently associated with an increased risk of breast cancer. Many states have enacted breast density notification laws requiring that patients be informed of their breast density and the potential need for supplemental screening with ultrasound or MRI.

<image>Panel A: Comparative mammography screening guideline chart showing ACOG, USPSTF, and ACS recommendations by age group with frequency of screening. Panel B: High-risk screening protocol diagram showing BRCA mutation carriers, chest radiation survivors, and strong family history patients with dual-modality MRI plus mammography timelines. Panel C: BI-RADS classification pyramid from Category 0 (incomplete) through Categories 1 and 2 (benign) to Categories 4 and 5 (biopsy recommended) and Category 6 (known malignancy). Panel D: Breast density classification with mammographic images showing Categories A through D and associated impact on screening sensitivity and cancer risk.</image>

### Section 8: Well-Woman Care

The annual well-woman visit serves as a comprehensive opportunity for health assessment, screening, and counseling. Components include an updated medical, surgical, and family history to identify new risk factors or changes in health status. The physical examination may include pelvic and breast examinations depending on clinical indication and screening guidelines, though a pelvic examination is no longer considered mandatory at every annual visit. Age-appropriate screening tests are ordered according to current evidence-based guidelines, and the visit provides an opportunity to update immunizations and address preventive health behaviors.

Screening recommendations for women span multiple organ systems and are guided by age and risk factors. Cervical cancer screening follows ASCCP guidelines from ages 21 to 65, while breast cancer screening with mammography begins between ages 40 and 50 depending on the guideline source. Colorectal cancer screening is now recommended beginning at age 45 and continuing through age 75. Sexually transmitted infection screening is risk-based and includes testing for chlamydia, gonorrhea, HIV, syphilis, and hepatitis B and C as appropriate. Osteoporosis screening with dual-energy X-ray absorptiometry is recommended at age 65 or earlier in women with risk factors, and lipid screening follows cardiovascular risk assessment guidelines.

Immunization counseling is an integral component of well-woman care across the lifespan. The HPV vaccine is recommended through age 26 with shared decision-making for adults aged 27 to 45 who have not been previously vaccinated. Tetanus, diphtheria, and pertussis vaccination with Tdap is given every 10 years, and influenza vaccination is recommended annually for all adults. COVID-19 vaccination follows current public health guidelines with updated boosters as recommended. Herpes zoster vaccination is indicated for adults aged 50 and older. Clinicians should review immunization status at each well-woman visit and administer vaccines according to the current Advisory Committee on Immunization Practices schedule.

Counseling on reproductive and behavioral health issues is a cornerstone of the well-woman visit. Contraceptive counseling addresses current and future family planning needs, ensures satisfaction with the chosen method, and provides an opportunity to discuss method switching if needed. Preconception counseling for women considering pregnancy includes recommendations for folic acid supplementation and optimization of chronic conditions. Menopause-related counseling addresses vasomotor symptoms, genitourinary syndrome of menopause, and long-term health implications. Sexual health discussions should address function and satisfaction, and intimate partner violence screening should be performed at every visit using a validated tool in a confidential setting.

<image>Panel A: Annual well-woman visit checklist showing components of history update, physical examination options, screening tests, immunizations, and counseling domains. Panel B: Age-based screening recommendation timeline for cervical cancer (21 to 65), breast cancer (40 to 50 onward), colorectal cancer (45 to 75), and osteoporosis (65 or risk-based). Panel C: Immunization schedule for women showing HPV (through 26), Tdap (every 10 years), influenza (annually), COVID-19 (per guidelines), and zoster (50 and older). Panel D: Counseling framework covering contraception, preconception planning, menopause management, sexual health assessment, and intimate partner violence screening.</image>

### Section 9: Vulvar and Vaginal Examination Findings

Vulvar lesions encompass a diverse range of conditions that may be identified during external examination. A Bartholin gland cyst or abscess presents as a swelling lateral to the vaginal introitus, typically at the 5 or 7 o'clock position, and may be asymptomatic when cystic or extremely painful when infected. Lichen sclerosus manifests as white, atrophic plaques that may cause intense pruritus and is associated with a small risk of vulvar squamous cell carcinoma. Lichen simplex chronicus produces thickened, lichenified skin resulting from chronic scratching and rubbing. Condylomata acuminata are genital warts caused by HPV, while vulvar intraepithelial neoplasia represents a premalignant condition that may appear as raised, pigmented, or white lesions, and vulvar cancer typically presents as an ulcerated or irregular mass.

Vaginal examination findings are assessed during speculum withdrawal and provide important diagnostic information. The normal vaginal mucosa is pink, rugated, and moist with adequate estrogenization. Atrophic vaginitis, common in postmenopausal women and those with hypoestrogenic states, presents with pale, smooth, dry mucosa that is friable and may bleed easily. Vaginal prolapse is assessed by having the patient perform a Valsalva maneuver, which may reveal a cystocele, rectocele, or uterine descent. Any vaginal lesion should be biopsied if its etiology is uncertain, particularly in postmenopausal women where malignancy must be excluded.

Vaginal discharge is a common presenting complaint that can be characterized by its appearance, odor, and associated symptoms. Normal physiologic discharge is white or clear, odorless, and varies in consistency with the menstrual cycle. Bacterial vaginosis produces a gray, thin, homogeneous discharge with a characteristic fishy odor and an elevated vaginal pH above 4.5. Vulvovaginal candidiasis causes a white, cottage cheese-like discharge accompanied by intense pruritus, erythema, and a normal pH. Trichomoniasis produces a green-yellow, frothy discharge that may be accompanied by a strawberry cervix appearance, while gonorrhea and chlamydia cause purulent cervicitis that may be identified during speculum examination.

Wet mount microscopy is a rapid, inexpensive diagnostic tool performed in the clinical setting to differentiate causes of vaginitis. A sample of vaginal discharge is placed on a glass slide with a drop of normal saline and examined under the microscope. Clue cells, which are vaginal epithelial cells studded with coccobacilli that obscure the cell border, are diagnostic of bacterial vaginosis. Hyphae and pseudohyphae indicate vulvovaginal candidiasis and are best visualized with the addition of potassium hydroxide, which lyses other cellular elements. Motile, flagellated trichomonads are pathognomonic for trichomoniasis, and an abundance of white blood cells indicates an inflammatory process that may suggest cervicitis, trichomoniasis, or desquamative inflammatory vaginitis.

<image>Panel A: Clinical photographs of vulvar lesions including Bartholin gland cyst at the vaginal introitus, white plaques of lichen sclerosus, lichenified skin of lichen simplex chronicus, and condylomata acuminata. Panel B: Comparative vaginal mucosal appearances showing normal pink rugated mucosa, pale atrophic mucosa, and vaginal prolapse with cystocele and rectocele. Panel C: Discharge comparison showing normal clear discharge, gray homogeneous discharge of bacterial vaginosis, white cottage cheese discharge of candidiasis, and green-yellow frothy discharge of trichomoniasis. Panel D: Wet mount microscopy images showing clue cells with adherent coccobacilli, branching hyphae and pseudohyphae, motile trichomonads with flagella, and abundant white blood cells indicating inflammation.</image>

### Section 10: Special Populations

Adolescent gynecologic care requires a developmentally appropriate approach that balances medical needs with the unique concerns of this age group. The first gynecologic visit is recommended between ages 13 and 15, primarily for education, counseling, and establishing a relationship rather than for pelvic examination. A pelvic examination is not routine in adolescents and is performed only when clinically indicated, such as for evaluation of abnormal bleeding, pelvic pain, or vaginal discharge. Sexually transmitted infection screening is offered to sexually active adolescents, and HPV vaccination is optimally administered at ages 11 to 12. Confidentiality is essential and should be discussed openly with both the patient and the accompanying parent or guardian, with clear boundaries established regarding what will and will not be shared.

Menopausal women present unique gynecologic considerations related to the cessation of ovarian function and declining estrogen levels. Genitourinary syndrome of menopause, formerly termed vulvovaginal atrophy, produces symptoms of vaginal dryness, dyspareunia, and urinary complaints that respond to local estrogen therapy. Postmenopausal bleeding is an alarm symptom that mandates evaluation to exclude endometrial cancer, typically beginning with transvaginal ultrasound to assess endometrial thickness. Pelvic organ prolapse increases in prevalence with age due to progressive loss of pelvic floor support, and osteoporosis screening and prevention become important components of care for postmenopausal women.

Patients with disabilities require thoughtful accommodations to ensure equitable access to gynecologic care. Adjustable examination tables that lower to wheelchair height facilitate safe transfers and positioning. Communication approaches should be tailored to the specific disability, utilizing sign language interpreters, large-print materials, or alternative communication devices as needed. Examination positioning may require modification from the standard lithotomy position, with lateral decubitus or other alternatives used when necessary. A trauma-informed care approach is particularly important in this population, as individuals with disabilities experience higher rates of abuse, and the clinician should be prepared to screen for and respond to disclosures of violence.

Care for LGBTQ+ patients begins with creating an inclusive and affirming clinical environment. Clinicians should use inclusive language and avoid assumptions about sexual orientation, gender identity, or sexual practices. Transgender men who retain a cervix require cervical cancer screening according to standard guidelines, and the clinician should be aware that speculum examination may be particularly uncomfortable due to testosterone-related vaginal atrophy. Sexually transmitted infection risk assessment should be based on specific sexual practices rather than identity categories. An affirming care environment includes appropriate pronoun use, gender-inclusive intake forms, and staff training on LGBTQ+ health competencies to reduce barriers to care and health disparities in this population.

<image>Panel A: Adolescent gynecology framework showing recommended first visit at ages 13 to 15, HPV vaccination at 11 to 12, indications for pelvic examination, and confidentiality discussion approach. Panel B: Menopausal patient evaluation pathway including genitourinary syndrome of menopause assessment, postmenopausal bleeding workup with ultrasound, prolapse screening, and osteoporosis prevention. Panel C: Disability accommodations for gynecologic examination showing adjustable table, communication aids, alternative positioning options, and trauma-informed care principles. Panel D: LGBTQ+ inclusive care elements including inclusive language examples, cervical screening for transgender men, practice-based STI risk assessment, and affirming clinical environment features.</image>

---

## Summary

- Menstrual history parameters include menarche at 10 to 16 years, cycle length of 24 to 38 days, duration of 4 to 8 days, and normal flow of 20 to 80 milliliters
- The pelvic examination consists of speculum examination to visualize the cervix and bimanual examination to assess the uterus and adnexa
- Cervical cancer screening starts at age 21, with HPV and cytology co-testing every 5 years preferred for women aged 30 to 65
- Bethesda cytology classification includes NILM, ASC-US, LSIL, HSIL, ASC-H, and AGC with management guided by result and HPV status
- HSIL management requires colposcopy with directed biopsy for histologic confirmation
- Clinical breast examination involves inspection in multiple positions and systematic palpation, with concerning findings including fixed, hard, or irregular masses
- Mammography screening starts between ages 40 and 50 depending on guidelines, performed annually or biennially
- BI-RADS categories range from 0 (incomplete) through 1 and 2 (benign), 3 (probably benign with short-interval follow-up), 4 and 5 (biopsy required), to 6 (known malignancy)
- Vaginal discharge evaluation uses wet mount microscopy to identify clue cells (bacterial vaginosis), hyphae (candidiasis), and trichomonads (trichomoniasis)
- Well-woman care includes annual visits with comprehensive history, age-appropriate screening, immunizations, and counseling across special populations

---

## Key Terms

| Term | Definition |
|------|------------|
| LMP | Last menstrual period |
| TPAL | Term, preterm, abortions, living |
| Transformation zone | Junction of squamous and columnar epithelium |
| ASC-US | Atypical squamous cells of undetermined significance |
| HSIL | High-grade squamous intraepithelial lesion |
| CIN | Cervical intraepithelial neoplasia |
| BI-RADS | Breast Imaging Reporting and Data System |
| Colposcopy | Magnified visualization of cervix |

---

*This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*